

# CJASN

Clinical Journal of the American Society of Nephrology

September 2014 • Vol. 9 • No. 9

## Editorials

---

- 1505 Checklists as Computer Decision Support at the Point of Care: A Step Forward in the Recognition and Treatment of CKD by Primary Care Physicians**  
*Chester Fox and Joseph Vassalotti*  
See related article on page 1526.
- 1507 Can Biomarkers of Disease Activity Guide Treatment in FSGS?**  
*Kirk N. Campbell and John C. He*  
See related article on page 1545.
- 1510 A Policy of Preemption: The Timing of Renal Replacement Therapy in AKI**  
*F. Perry Wilson*  
See related article on page 1577.
- 1513 Can Oral Therapy Reduce Uremic Toxins?**  
*Thomas A. Depner and Larry D. Cowgill*  
See related article on page 1603.
- 1516 Factors Influencing Treatment of Atypical Hemolytic Uremic Syndrome**  
*Carla M. Nester and Richard J.H. Smith*  
See related article on page 1611.

## Original Articles

---

### Chronic Kidney Disease

- 1519 Medication Adherence and Growth in Children with CKD**  
*Oleh M. Akchurin, Michael F. Schneider, Lucy Mulqueen, Ellen R. Brooks, Craig B. Langman, Larry A. Greenbaum, Susan L. Furth, Marva Moxey-Mims, Bradley A. Warady, Frederick J. Kaskel, and Amy L. Skversky*
- 1526 Implementation of a CKD Checklist for Primary Care Providers**  
*Mallika L. Mendu, Louise I. Schneider, Ayal A. Aizer, Karandeep Singh, David E. Leaf, Thomas H. Lee, and Sushrut S. Waikar*  
See related editorial on page 1505.
- 1536 Preoperative Hemoglobin and Outcomes in Patients with CKD Undergoing Cardiac Surgery**  
*Linda Shavit, Sharbel Hitti, Shuli Silberman, Rachel Tauber, Ofer Merin, Meyer Lifschitz, Itzhak Slotki, Daniel Bitran, and Daniel Fink*
- 1545 Evaluation of MicroRNAs miR-196a, miR-30a-5P, and miR-490 as Biomarkers of Disease Activity among Patients with FSGS**  
*Wanfen Zhang, Changming Zhang, Huimei Chen, Limin Li, Yuanmao Tu, Chunbei Liu, Shaolin Shi, Ke Zen, and Zhihong Liu*  
See related editorial on page 1507.
- 1553 Kidney Function and Plasma Copeptin Levels in Healthy Kidney Donors and Autosomal Dominant Polycystic Kidney Disease Patients**  
*Debbie Zittema, Else van den Berg, Esther Meijer, Wendy E. Boertien, Anneke C. Muller Kobold, Casper F.M. Franssen, Paul E. de Jong, Stephan J.L. Bakker, Gerjan Navis, and Ron T. Gansevoort*

Clinical Nephrology

**1563 Safety and Efficacy of Tandem Hemodialysis and Plasma Exchange in Children**

*Betti Schaefer, Akos Ujszaszi, Susanne Schaefer, Karl Heinz Heckert, Franz Schaefer, and Claus Peter Schmitt*

**1571 Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis**

*Michael Walsh, Mikkel Faurshou, Annelies Berden, Oliver Flossmann, Ingeborg Bajema, Peter Høglund, Rona Smith, Vladimir Szpirt, Kerstin Westman, Charles D. Pusey, and David R.W. Jayne, for the European Vasculitis Study Group*

Critical Care Nephrology

**1577 Timing of RRT Based on the Presence of Conventional Indications**

*Suvi T. Vaara, Matti Reinikainen, Ron Wald, Sean M. Bagshaw, Ville Pettilä, and The FINNAKI Study Group*  
See related editorial on page 1510.

Epidemiology and Outcomes

**1586 Risk of ESRD and Death in Patients with CKD Not Referred to a Nephrologist: A 7-Year Prospective Study**

*Roberto Minutolo, Francesco Lapi, Paolo Chiodini, Monica Simonetti, Elisa Bianchini, Serena Pecchioli, Iacopo Cricelli, Claudio Cricelli, Gaetano Piccinocchi, Giuseppe Conte, and Luca De Nicola*

ESRD and Chronic Dialysis

**1594 Associations of Depressive Symptoms and Pain with Dialysis Adherence, Health Resource Utilization, and Mortality in Patients Receiving Chronic Hemodialysis**

*Steven D. Weisbord, Maria K. Mor, Mary Ann Sevick, Anne Marie Shields, Bruce L. Rollman, Paul M. Palevsky, Robert M. Arnold, Jamie A. Green, and Michael J. Fine*

**1603 Effect of Increasing Dietary Fiber on Plasma Levels of Colon-Derived Solutes in Hemodialysis Patients**

*Tammy L. Sirich, Natalie S. Plummer, Christopher D. Gardner, Thomas H. Hostetter, and Timothy W. Meyer*  
See related editorial on page 1513.

Genetics

**1611 Complement Mutations in Diacylglycerol Kinase- $\epsilon$ -Associated Atypical Hemolytic Uremic Syndrome**

*Daniel Sánchez Chinchilla, Sheila Pinto, Bernd Hoppe, Marta Adragna, Laura Lopez, Maria Luisa Justa Roldan, Antonia Peña, Margarita Lopez Trascasa, Pilar Sánchez-Corral, and Santiago Rodríguez de Córdoba*  
See related editorial on page 1516.

Mineral Metabolism/Bone Disease

**1620 A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3–4 CKD**

*Daniel W. Coyne, Seth Goldberg, Mark Faber, Cybele Ghossein, and Stuart M. Sprague*

---

Renal Physiology

**1627 Proximal Tubule Function and Response to Acidosis**

*Norman P. Curthoys and Orson W. Moe*

---

Commentary

**1639  Training the Next Generation's Nephrology Workforce**

*Jeffrey S. Berns, David H. Ellison, Stuart L. Linas, and Mitchell H. Rosner*

**1645 The Approval Process for Biosimilar Erythropoiesis-Stimulating Agents**

*Jay B. Wish*

### 1652 The Ethics of Offering Dialysis for AKI to the Older Patient: Time to Re-Evaluate?


*Sana Akbar and Alvin H. Moss*

## In-Depth Review

---

### 1657 Is Newer Safer? Adverse Events Associated with First-Line Therapies for ANCA-Associated Vasculitis and Lupus Nephritis

*Jonathan Hogan, Rupali Avasare, and Jai Radhakrishnan*

 eJournal club provides a timely and interactive electronic journal club experience by offering a forum in which CJASN readers have the opportunity to converse with the featured study authors. Visit [ejc.cjasn.org](http://ejc.cjasn.org) to learn more.

#### On the Cover

*What's the diagnosis?* A 33-year-old woman with unremarkable past medical history except for a diagnosis of atypical migraine headaches 6 months ago recently noted the acute onset of mild ankle swelling that rapidly worsened and progressed to involve her upper thighs. In addition, she noted increasing fatigue and malaise, 25 pound weight gain, and loss of appetite. Her only medications included oral contraception pill, multi-vitamins, and occasional naproxen for headaches. On evaluation in an ambulatory care clinic, physical examination revealed 3+ pitting edema of her lower extremities including her thighs. There were no joint swelling, skin rash or other abnormal exam findings. Serum chemistries were notable for normal electrolytes, BUN 45 mg/dl, serum creatinine 4.3 mg/dl, and serum albumin 2.1 g/dl. Urinalysis revealed SG 1.014, pH 5.5, 3+ protein, negative blood, and trace leukocytes. Urine microscopy demonstrated 1-3 renal tubular epithelial cells/HPF, 0-2 white blood cells/HPF, 2-6 oval fat bodies /HPF, and 1-2 lipid casts/LPF. 24-hour urine collection contained 8.6 grams of protein. The patient underwent kidney biopsy for AKI and nephrotic syndrome, which revealed diffuse interstitial infiltrate containing lymphocytes, PMNs and eosinophils (left panel) consistent with drug-induced acute interstitial nephritis (AIN). The right panel shows globally effaced foot processes without deposits consistent with minimal change disease (MCD). The combination of eosinophil-dominant AIN and MCD pointed to naproxen as the underlying cause of the kidney lesion. Naproxen was discontinued and oral prednisone (60 mg/day) was administered for 4 weeks followed by taper with improvement in kidney function (serum creatinine 1.3 mg/dl) and resolution of proteinuria. NSAID-induced renal syndromes include a number of electrolyte/acid-base and other kidney lesions. In this case, naproxen caused 2 of those lesions—AIN and MCD. The mechanism by which these 2 lesions develop with NSAIDs is not known, but is speculated to be due to shunting of arachidonic acid pathway into the lipoygenase pathway with production of proinflammatory and vasoactive leukotrienes. It is possible that leukotrienes promote interstitial inflammation and injure glomerular epithelial cells (podocytes). Therapy consists of NSAID discontinuation, and steroids if kidney function and nephrotic proteinuria do not improve. In general, patients recover from this renal lesion, but permanent chronic kidney disease may occur later. (Images and text provided by Gilbert Moeckel, MD and Mark A. Perazella, MD, Yale University School of Medicine, New Haven, Connecticut)